Remember, there is a political aspect to all of this. BP contributes 80%+ to fund these agencies; therefore, they have a huge influence over decisions. So, it wouldn't sit well with Lilly, especially, if little Anavex had an easier path to approval than Lilly.
So, to receive a negative trend rather than an outright rejection (like donanemab) is a bit of a victory, with re-examination and additional data to follow.
This better, safer, simpler, and cheaper drug (blarcamesine) will eventually be approved. IMO
Market Data 
Markets 
AI
